Literature DB >> 19608712

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.

Atsushi Mizokami1, Eitetsu Koh, Kouji Izumi, Kazutaka Narimoto, Masashi Takeda, Seijiro Honma, Jinlu Dai, Evan T Keller, Mikio Namiki.   

Abstract

One of the mechanisms through which advanced prostate cancer (PCa) usually relapses after androgen deprivation therapy (ADT) is the adaptation to residual androgens in PCa tissue. It has been observed that androgen biosynthesis in PCa tissue plays an important role in this adaptation. In the present study, we investigated how stromal cells affect adrenal androgen dehydroepiandrosterone (DHEA) metabolism in androgen-sensitive PCa LNCaP cells. DHEA alone had little effect on prostate-specific antigen (PSA) promoter activity and the proliferation of LNCaP cells. However, the addition of prostate stromal cells or PCa-derived stromal cells (PCaSC) increased DHEA-induced PSA promoter activity via androgen receptor activation in the LNCaP cells. Moreover, PCaSC stimulated the proliferation of LNCaP cells under physiological concentrations of DHEA. Biosynthesis of testosterone or dihydrotestosterone from DHEA in stromal cells and LNCaP cells was involved in this stimulation of LNCaP cell proliferation. Androgen biosynthesis from DHEA depended upon the activity of various steroidogenic enzymes present in stromal cells. Finally, the dual 5alpha-reductase inhibitor dutasteride appears to function not only as a 5alpha-reductase inhibitor but also as a 3beta-hydroxysteroid dehydrogenase inhibitor in LNCaP cells. Taken together, this coculture assay system provides new insights of coordinate androgen biosynthesis under the microenvironment of PCa cells before and after ADT, and offers a model system for the identification of important steroidogenic enzymes involved in PCa progression and for the development of the corresponding inhibitors of androgen biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608712     DOI: 10.1677/ERC-09-0070

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

Review 1.  New hormonal therapies for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephen Plymate
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-14       Impact factor: 4.741

Review 2.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

3.  Transforming growth factor β1 increase of hydroxysteroid dehydrogenase proteins is partly suppressed by red clover isoflavones in human primary prostate cancer-derived stromal cells.

Authors:  Xunxian Liu; Yun-Shang Piao; Julia T Arnold
Journal:  Carcinogenesis       Date:  2011-09-12       Impact factor: 4.944

Review 4.  Androgen action and metabolism in prostate cancer.

Authors:  Sean M Green; Elahe A Mostaghel; Peter S Nelson
Journal:  Mol Cell Endocrinol       Date:  2012-03-20       Impact factor: 4.102

5.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

Review 6.  Blockade of testicular and adrenal androgens in prostate cancer treatment.

Authors:  Fernand Labrie
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

7.  Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.

Authors:  Arja Kaipainen; Ailin Zhang; Rui M Gil da Costa; Jared Lucas; Brett Marck; Alvin M Matsumoto; Colm Morrissey; Lawrence D True; Elahe A Mostaghel; Peter S Nelson
Journal:  Prostate       Date:  2019-08-02       Impact factor: 4.104

8.  Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

Authors:  Haveesh Sharma; Tristan M Sissung; Heather Pressler; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-02-06       Impact factor: 4.742

9.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

10.  Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.

Authors:  Agus Rizal A H Hamid; Minja J Pfeiffer; Gerald W Verhaegh; Ewout Schaafsma; Andre Brandt; Fred C G J Sweep; John P M Sedelaar; Jack A Schalken
Journal:  Mol Med       Date:  2013-01-22       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.